Shanghai Haihe Biopharma Co., Ltd. announced that it has entered into an financing agreement and received $146.6 million in its series B round of funding led by HG Healthcare Venture Capital Chengdu Partnership Enterprise (Limited Partnership), a fund managed by Beijing HuaGai Healthcare Investment Management Co., Ltd. on February 11, 2019. The transaction also included participation from CSPC Pharmaceutical Group Limited (SEHK:1093), DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:A067080), Hillhouse Capital Management, Ltd., Boyuan Capital Limited, Atlas Capital, Yingke Innovation Asset Management Co., Ltd., Elite Capital, CAS Venture Capital Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10,830 KRW | -4.16% |
|
+2.27% | +15.46% |
1st Jan change | Capi. | |
---|---|---|
+15.46% | 143M | |
+34.09% | 10.31B | |
+40.41% | 5.23B | |
-15.24% | 4.62B | |
+11.62% | 3.52B | |
+26.25% | 2.31B | |
-38.78% | 1.78B | |
-44.54% | 1.69B | |
-0.50% | 1.64B | |
+0.10% | 1.59B |
- Stock Market
- Equities
- A067080 Stock
- News DAE HWA Pharmaceutical Co., Ltd.
- Shanghai Haihe Biopharma Co., Ltd. announced that it has received $146.6 million in funding from a group of investors